NasdaqGS:SNDX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Syndax Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SNDX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: SNDX's weekly volatility has decreased from 16% to 10% over the past year.


Market Performance


7 Day Return

-1.5%

SNDX

3.9%

US Biotechs

0.7%

US Market


1 Year Return

214.3%

SNDX

24.7%

US Biotechs

22.2%

US Market

Return vs Industry: SNDX exceeded the US Biotechs industry which returned 26.3% over the past year.

Return vs Market: SNDX exceeded the US Market which returned 22.7% over the past year.


Shareholder returns

SNDXIndustryMarket
7 Day-1.5%3.9%0.7%
30 Day33.4%14.0%11.8%
90 Day46.2%14.9%8.6%
1 Year214.3%214.3%26.8%24.7%25.0%22.2%
3 Year189.2%189.2%27.7%21.1%49.4%39.5%
5 Yearn/a17.3%9.2%100.2%78.1%

Long-Term Price Volatility Vs. Market

How volatile is Syndax Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Syndax Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

6.71x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SNDX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SNDX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SNDX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SNDX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SNDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SNDX is overvalued based on its PB Ratio (6.7x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Syndax Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

0.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNDX's revenue (85.1% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: SNDX's revenue (85.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SNDX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Syndax Pharmaceuticals performed over the past 5 years?

6.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SNDX is currently unprofitable.

Growing Profit Margin: SNDX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SNDX is unprofitable, but has reduced losses over the past 5 years at a rate of 6.4% per year.

Accelerating Growth: Unable to compare SNDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: SNDX has a negative Return on Equity (-50.57%), as it is currently unprofitable.


Next Steps

Financial Health

How is Syndax Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: SNDX's short term assets ($177.4M) exceed its short term liabilities ($15.2M).

Long Term Liabilities: SNDX's short term assets ($177.4M) exceed its long term liabilities ($32.2M).


Debt to Equity History and Analysis

Debt Level: SNDX's debt to equity ratio (15.2%) is considered satisfactory.

Reducing Debt: SNDX's debt to equity ratio has increased from 11.3% to 15.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SNDX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SNDX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 29% each year.


Next Steps

Dividend

What is Syndax Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SNDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SNDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SNDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SNDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

Briggs Morrison (60 yo)

5.5yrs

Tenure

US$1,612,004

Compensation

Dr. Briggs W. Morrison, M.D. serves as Director at Repare Therapeutics Inc since June 2017. He joined MPM in 2015. He served as the Chairman of Scientific Advisory Board at ABIONYX Pharma SA (formerly, Cer...


CEO Compensation Analysis

Compensation vs Market: Briggs's total compensation ($USD1.61M) is below average for companies of similar size in the US market ($USD2.60M).

Compensation vs Earnings: Briggs's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Briggs Morrison
CEO & Director5.5yrsUS$1.61m0.11%
$ 1.1m
Michael Metzger
President1.42yrsUS$2.70m0.043%
$ 401.8k
Michael Meyers
Chief Medical Officer & Senior VP5.33yrsUS$818.47k0.026%
$ 244.1k
Peter Ordentlich
Co-Founder & Chief Scientific Officer15.17yrsno datano data
Richard Heyman
Co-Founderno datano datano data
Ronald Evans
Co-Founder4.42yrsno datano data
Michael Downes
Co-Founderno datano datano data
Daphne Karydas
Chief Financial Officer0.42yrno datano data
Luke Albrecht
Senior VP4.33yrsno datano data
Edward Sausville
no datano datano data
Jean-Pierre Issa
no datano datano data
Sue Eckhardt
no datano datano data

5.4yrs

Average Tenure

55.5yo

Average Age

Experienced Management: SNDX's management team is seasoned and experienced (5.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Briggs Morrison
CEO & Director5.5yrsUS$1.61m0.11%
$ 1.1m
Michael Metzger
President1.42yrsUS$2.70m0.043%
$ 401.8k
Ronald Evans
Co-Founder4.42yrsno datano data
Jay Lichter
Observerno datano datano data
Keith Katkin
Independent Director3.75yrsUS$221.25k0%
$ 0
Pierre Legault
Independent Director3.92yrsUS$223.25k0%
$ 0
Dennis Podlesak
Independent Chairman12yrsUS$369.46k0%
$ 0
George Sledge
Member of Scientific Advisory Board3.67yrsUS$23.05kno data
Fabrice Egros
Independent Director7.25yrsUS$174.25k0%
$ 0
Samir Khleif
Member of Scientific Advisory Board4.42yrsno datano data
Julie Brahmer
Member of Scientific Advisory Board5yrsno datano data
Joseph Eder
Member of Scientific Advisory Board4.42yrsno datano data

4.4yrs

Average Tenure

58yo

Average Age

Experienced Board: SNDX's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 50.6%.


Top Shareholders

Company Information

Syndax Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Syndax Pharmaceuticals, Inc.
  • Ticker: SNDX
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$929.775m
  • Shares outstanding: 40.87m
  • Website: https://www.syndax.com

Number of Employees


Location

  • Syndax Pharmaceuticals, Inc.
  • 35 Gatehouse Drive
  • Building D
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1T3DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2016
SNDXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2016

Biography

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s lead product candidates are entinostat that is in Phase III clinical ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/02 23:08
End of Day Share Price2020/12/02 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.